Pharmaceuticals

LIVZON GROUP

Lizhu Pharmaceutical Announces Q1 2026 Financial Report

LIVZON GROUP released FY2026 Q1 earnings on April 23 Pre-Market (BJT), actual revenue CNY 2.871 B (forecast CNY 3.172 B), actual EPS CNY 0.65 (forecast CNY 0.72)

LIVZON GROUP to Release FY2026 Q1 Earnings on April 23 Pre-Market (BJT), Forecast Revenue CNY 3.172 B, EPS CNY 0.72

Lizhu Pharmaceutical Subsidiary Granted Clinical Trial Approval for Injectable Brexpiprazole Microsphere

LIVZON GROUP released FY2025 earnings on March 24 After-Market (BJT), actual revenue CNY 12.02 B (forecast CNY 12.17 B), actual EPS CNY 2.2654 (forecast CNY 2.3781)

LIVZON GROUP released FY2025 Q4 earnings on March 24 After-Market (BJT), actual revenue CNY 2.904 B (forecast CNY 2.814 B), actual EPS CNY 0.3057 (forecast CNY 0.37)

LIVZON GROUP to Release FY2025 Earnings on March 24 Pre-Market (BJT), Forecast Revenue CNY 12.17 B, EPS CNY 2.3781

Lizhu Group's Subsidiary and Beijing XinKanghe Jointly Developed Lekangqita Monoclonal Antibody Injection Included in Priority Review List

Lizhu Pharmaceutical Extends Equity Transfer Deadline for Acquisition of Vietnamese Listed Company Imexpharm Corporation to June 30, 2026

Lizhu Pharmaceutical Plans Public Tender Offer to Acquire Shares of Imexpharm Corporation

Lizhu Pharmaceutical and XinKangHe BioMed's Lekangqita Injection Receives NMPA Marketing Authorization Application Acceptance

Lizhu Pharmaceutical Factory Obtains Approval for NS-041 Tablet's New Clinical Trial for Depression

Lizhu Pharmaceutical Donates 10 Million HKD to Support Victims of Hong Kong Fire

Lizhu Pharmaceutical repurchased 160,100 A-shares

Lizhu Pharmaceutical Repurchased 164,000 A-shares for 5.9969 Million Yuan

2025 National Medical Insurance Catalog Negotiation Launched

LIVZON GROUP released FY2025 9 Months Earnings on October 23 Pre-Market (BJT), actual revenue CNY 9.116 B, actual EPS CNY 1.9593

LIVZON GROUP released FY2025 Q3 earnings on October 23 Pre-Market (BJT), actual revenue CNY 2.844 B (forecast CNY 2.821 B), actual EPS CNY 0.5295 (forecast CNY 0.6)

LIVZON GROUP to Release FY2025 Q3 Earnings on October 23 Pre-Market (BJT), Forecast Revenue CNY 2.821 B, EPS CNY 0.6

Lizhu Group's Secretary Responds to Investor Questions

000513

01513

Livzon Pharmaceutical Group reported a decline in first-quarter 2026 results, with operating income of RMB2.871 billion and net profit of RMB577 million, down 9.73% and 9.39% year-on-year, respectively. The decrease is attributed to industry policy adjustments and seasonal demand fluctuations. However, net cash flow from operating activities increased by 12.8% to RMB817 million, and shareholders’ equity rose by 4.47%. The company maintains a stable balance sheet with total assets at RMB24.19 billion. Analysts currently rate the stock as a Sell with a price target of HK$22.99.

Tip Ranks

LIVZON PHARMA

Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue

520690

159506

510660

159316

Livzon Pharmaceutical Outlines Board and Committee Structure

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Hwabao WP CSI Pharmaceuticals ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Livzon Pharmaceutical Outlines Board and Committee Structure

LIVZON PHARMA announced that it has entered into a supplementary agreement with the sellers SK Investment, Sunrise, and KBA regarding the acquisition of a total of 64.81% equity in the Vietnamese listed company Imexpharm Corporation, which extends the completion date to June 30, 2026. The adjusted maximum cash consideration for this transaction is 6.891 trillion Vietnamese Dong (approximately 1.846 billion RMB)

AASTOCKS

LIVZON PHARMA adjusts the maximum cost of acquiring its Vietnamese peer to RMB 1.85 billion

LIVZON PHARMA announced that its holding subsidiary, LIVZON Monoclonal Antibody, received a notification from the National Medical Products Administration. The application for the domestic production drug registration and marketing authorization of the monoclonal antibody injection, jointly developed with Beijing Xinkanghe, has been accepted. The intended indication is for adult patients with moderate to severe plaque psoriasis suitable for systemic therapy or phototherapy

LIVZON PHARMA's application for marketing authorization of Lecanemab injection has been accepted

According to the Zhitong Finance APP, LIVZON PHARMA announced that on November 3, 2025, the company spent RMB 5.9969 million to repurchase 164,000 A shares, with a repurchase price ranging from RMB 36.34 to RMB 36.70 per share

Zhitong

On November 3rd, LIVZON PHARMA spent CNY 5.9969 million to repurchase 164,000 A shares

According to the Zhitong Finance APP, LIVZON GROUP announced that as of October 31, 2025, the company repurchased a total of 15.3768 million A shares through centralized bidding, accounting for 1.70% of the company's total share capital, with a total amount of funds used being 570 million yuan (excluding transaction fees)

LIVZON GROUP has repurchased 1.7% of its shares at a cost of 570 million yuan

The negotiation for the National Medical Insurance Catalog in 2025 officially started today. Reporters on-site learned that around 1:30 PM, the participating companies included Boehringer Ingelheim, Pfizer, Qilu Pharmaceutical, Kangyuan Pharmaceutical, Baile Pharmaceutical, Shengdi Pharmaceutical, Fosun Pharma, and Fresenius Kabi, among others. Earlier in the morning, the participating companies included LIVZON PHARMA, Innovent Biologics, Roche, and AstraZeneca

Pfizer

Directly hitting the afternoon of the first day of the 2025 National Conference: Pfizer, Qilu, and many other Chinese and foreign companies enter the venue

According to the Zhitong Finance APP, LIVZON PHARMA released its performance for the first three quarters of 2025, with the group achieving operating revenue of 9.116 billion yuan, an increase of 0.38% year-on-year; net profit attributable to the company's shareholders was 1.754 billion yuan, an increase of 4.86% year-on-year; basic earnings per share were 1.96 yuan

LIVZON PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 1.754 billion yuan, an increase of 4.86% year-on-year

According to the Zhitong Finance APP, LIVZON PHARMA announced that as of September 30, 2025, the company repurchased a total of 15.3768 million A-shares through centralized bidding, accounting for 1.70% of the company's total share capital. The highest purchase price was RMB 41.99 per share, and the lowest price was RMB 33.21 per share, with a total amount of funds used being RMB 570 million (excluding transaction fees). The above repurchase is in line with the company's established share repurchase plan

As of the end of September, LIVZON PHARMA has repurchased a total of 15.3768 million A shares

LIVZON GROUP(000513.SZ)

Livzon Pharmaceutical’s First-Quarter Profit Slips as Policy Shift and Seasonality Hit Revenue

Livzon Pharmaceutical Outlines Board and Committee Structure

LIVZON PHARMA adjusts the maximum cost of acquiring its Vietnamese peer to RMB 1.85 billion

LIVZON PHARMA's application for marketing authorization of Lecanemab injection has been accepted

On November 3rd, LIVZON PHARMA spent CNY 5.9969 million to repurchase 164,000 A shares

LIVZON GROUP has repurchased 1.7% of its shares at a cost of 570 million yuan

Directly hitting the afternoon of the first day of the 2025 National Conference: Pfizer, Qilu, and many other Chinese and foreign companies enter the venue

LIVZON PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 1.754 billion yuan, an increase of 4.86% year-on-year

As of the end of September, LIVZON PHARMA has repurchased a total of 15.3768 million A shares